| Literature DB >> 23984066 |
Jin Iwazawa1, Shoichi Ohue, Naoko Hashimoto, Takashi Mitani.
Abstract
Purpose. To compare the number of image acquisitions and procedural time required for transarterial chemoembolization (TACE) with and without tumor-feeder detection software in cases of hepatocellular carcinoma (HCC). Materials and Methods. We retrospectively reviewed 50 cases involving software-assisted TACE (September 2011-February 2013) and 84 cases involving TACE without software assistance (January 2010-August 2011). We compared the number of image acquisitions, the overall procedural time, and the therapeutic efficacy in both groups. Results. Angiography acquisition per session reduced from 6.6 times to 4.6 times with software assistance (P < 0.001). Total image acquisition significantly decreased from 10.4 times to 8.7 times with software usage (P = 0.004). The mean procedural time required for a single session with software-assisted TACE (103 min) was significantly lower than that for a session without software (116 min, P = 0.021). For TACE with and without software usage, the complete (68% versus 63%, resp.) and objective (78% versus 80%, resp.) response rates did not differ significantly. Conclusion. In comparison with software-unassisted TACE, automated feeder-vessel detection software-assisted TACE for HCC involved fewer image acquisitions and could be completed faster while maintaining a comparable treatment response.Entities:
Year: 2013 PMID: 23984066 PMCID: PMC3745970 DOI: 10.1155/2013/580839
Source DB: PubMed Journal: Radiol Res Pract ISSN: 2090-195X
Baseline patient and tumor characteristics.
| TACE |
| ||
|---|---|---|---|
| With software | Without software | ||
| Gender (female/male) | 21/29 | 29/55 | 0.390 |
| Age (years)* | 73 (37–90) | 71 (35–89) | 0.079 |
| HBs antigen (positive/negative) | 5/45 | 15/69 | 0.220 |
| HCV antibody (positive/negative) | 38/12 | 60/24 | 0.567 |
| Child-Pugh class (A/B) | 42/8 | 60/24 | 0.100 |
| TNM stage (I/II/III) | 12/27/11 | 24/44/16 | 0.537 |
| Serum AFP level (ng/mL)* | 609 (3–12424) | 173 (3–3557) | 0.191 |
| Previous treatment (primary/recurrence) | 13/37 | 23/61 | 0.864 |
| Number of tumors (1/2/3/4/5 or greater) | 19/10/6/7/8 | 42/12/10/8/12 | 0.258 |
| Maximum tumor size (mm)* | 21 (9–47) | 21 (8–61) | 0.623 |
| Number of treatment areas in a single session* | 1.7 (1–4) | 1.6 (1–4) | 0.329 |
| Treatment area (distal/subsegment/segment/lobe) | 20/47/11/9 | 21/72/22/19 | 0.111 |
*Data are expressed as the mean (range).
TACE: transarterial chemoembolization.
HB: hepatitis B; HCV: hepatitis C virus; AFP: α-fetoprotein.
Figure 1Images from a patient with hepatocellular carcinoma undergoing transarterial chemoembolization with the assistance of automated feeder-vessel detection software. (a) The common hepatic artery angiogram shows the target tumor (arrow) at the right hepatic dome. Identifying the complex arterial vasculature of the tumor feeder is difficult. (b) The volume-rendered C-arm computed tomography (CT) image, showing the extracted tumor feeder by the software as a path from the catheter to the target (arrow) indicated in green. (c) Selective catheterization directly into the suggested feeder artery, based on the software analysis, shows tumor enhancement (arrow). (d) The axial C-arm CT image, obtained during contrast injection from the same feeder artery, confirms target enhancement (arrow) in association with the treatment area.
Number of image acquisitions required for a single session of chemoembolization.
| Imaging | Tumor multiplicity | Number of image acquisition |
| |
|---|---|---|---|---|
| TACE with software | TACE without software | |||
| Angiography | Single ( | 3.7 ± 1.0 (2–6) | 6.3 ± 1.7 (3–10) | <0.001 |
| Multiple ( | 5.2 ± 1.9 (2–10) | 7.0 ± 2.4 (4–14) | 0.001 | |
| Overall | 4.6 ± 1.7 (2–10) | 6.6 ± 2.1 (3–14) | <0.001 | |
|
| ||||
| C-arm CT | Single ( | 3.4 ± 1.3 (2–7) | 3.4 ± 1.5 (2–8) | 0.884 |
| Multiple ( | 4.4 ± 1.4 (2–7) | 4.0 ± 1.2 (2–7) | 0.215 | |
| Overall | 4.1 ± 1.4 (2–7) | 3.8 ± 1.4 (2–8) | 0.228 | |
|
| ||||
| Total | Single ( | 7.1 ± 1.8 (5–12) | 9.7 ± 3.0 (5–17) | 0.001 |
| Multiple ( | 9.6 ± 2.7 (5–16) | 11.0 ± 3.2 (6–20) | 0.105 | |
| Overall | 8.7 ± 2.7 (5–16) | 10.4 ± 3.2 (5–20) | 0.004 | |
Data are expressed as mean ± standard deviation (range).
TACE: transarterial chemoembolization.
C-arm CT: C-arm computed tomography.
Procedural time required for a single chemoembolization.
| Tumor multiplicity | Procedural time (min) |
| |
|---|---|---|---|
| TACE with software | TACE without software | ||
| Single ( | 88 ± 22 (44–132) | 109 ± 29 (58–187) | 0.013 |
| Multiple ( | 112 ± 35 (50–178) | 123 ± 32 (67–228) | 0.219 |
|
| |||
| Overall | 103 ± 33 (44–178) | 116 ± 31 (58–228) | 0.021 |
Data are expressed as mean ± standard deviation (range).
TACE: transarterial chemoembolization.
Therapeutic efficacy of chemoembolization of hepatocellular carcinoma.
| TACE with software | TACE without software |
| |
|---|---|---|---|
| CR | 34 | 53 | 0.728 |
| PR | 5 | 15 | |
| SD | 6 | 8 | |
| PD | 5 | 8 | |
|
| |||
| CR rate (%) | 68 | 63 | 0.565 |
| OR rate (%) | 78 | 80 | 0.680 |
The response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors [4].
CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; OR: objective response; TACE: transarterial chemoembolization.